NASH: Wall Street's forgotten mega blockbuster indication Published: Dec 12, 2022 By George Budwell BioSpace Wall Street loves a juicy value proposition. Over the course of 2014 to 2018, publicly traded drugmakers with assets in the nonalcoholic steatohepatitis (NASH) space were in vogue among retail and institutional investors alike. NASH rose to prominence in the investing world during this period for four key reasons: Intercept Pharmaceuticals, for example, was gearing up to evaluate its selective FXR agonist, Ocaliva (obeticholic acid), in a registration-enabling Phase III study for NASH. And in mid-2018, Madrigal Pharmaceuticals announced positive Phase II results for its thyroid hormone receptor beta agonist, resmetirom, as a treatment for this serious liver ailment, thereby setting the stage for another promising compound to enter late-stage testing.